BioAtla, Inc. (BCAB)
OTCMKTS · Delayed Price · Currency is USD
1.330
+0.020 (1.53%)
At close: Oct 20, 2026
BioAtla Revenue
BioAtla had revenue of $6.50M in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $8.50M, down -22.73% year-over-year. In the year 2025, BioAtla had annual revenue of $2.00M, down -81.82%. That makes BioAtla the 38,052nd largest company in the world by revenue and 5,000th in the United States.
Revenue (ttm)
8.50M
Revenue Growth
-22.73%
P/S Ratio
0.26
Revenue / Employee
207.32K
Employees
41
Market Cap
2.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | -9.00M | -81.82% |
| Dec 31, 2024 | 11.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 250.00K | -179.00K | -41.72% |
| Dec 31, 2020 | 429.00K | -4.77M | -91.75% |
| Dec 31, 2019 | 5.20M | -5.43M | -51.07% |
| Dec 31, 2018 | 10.63M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CASI Pharmaceuticals | 20.11M |
| International Stem Cell | 9.51M |
| Pacific Software | 2.40M |
| Vaccinex | 601.00K |
| GPL Holdings | 376.54K |
| Enzolytics | 46.59K |
| Affymax | 42.00K |
BioAtla News
- 1 day ago - BioAtla Registration statement: Registration filing - Filings
- 2 months ago - BioAtla Quarterly report: Q2 2026 - Filings
- 4 months ago - BioAtla Proxy statement: Proxy filing - Filings
- 4 months ago - BioAtla Proxy statement: Proxy filing - Filings
- 5 months ago - Context Therapeutics enters license agreement amendment with BioAtla - TheFly
- 5 months ago - BioAtla Quarterly report: Q1 2026 - Filings
- 6 months ago - BioAtla trading halted, news pending - TheFly
- 6 months ago - BioAtla announces 50-for-1 share consolidation - TheFly